KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Payables (2016 - 2026)

Pacific Biosciences Of California has reported Payables over the past 16 years, most recently at $20.8 million for Q4 2025.

  • For Q4 2025, Payables rose 25.2% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $20.8 million, up 25.2%, while the annual FY2025 figure was $20.8 million, 25.2% up from the prior year.
  • Payables for Q4 2025 was $20.8 million at Pacific Biosciences Of California, up from $16.4 million in the prior quarter.
  • Over five years, Payables peaked at $21.0 million in Q1 2024 and troughed at $3.5 million in Q1 2021.
  • A 5-year average of $14.6 million and a median of $15.6 million in 2023 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 35.97% in 2021 and later surged 407.26% in 2022.
  • Year by year, Payables stood at $12.6 million in 2021, then rose by 13.62% to $14.3 million in 2022, then grew by 8.61% to $15.6 million in 2023, then rose by 6.61% to $16.6 million in 2024, then rose by 25.2% to $20.8 million in 2025.
  • Business Quant data shows Payables for PACB at $20.8 million in Q4 2025, $16.4 million in Q3 2025, and $15.1 million in Q2 2025.